OB/GYNs, Primary Care Physicians, Nurse Practitioners, Physician's Assistants, Endocrinologists
Women's Health, Vulvovaginal atrophy, Genitourinary Syndrome of Menopause
1. | Discuss how the science of Intracrinology and DHEA relates to the physiologic, histologic and morphologic changes associated with menopause and treatment of dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM), and potentially Hypoactive Sexual Desire Disorder (HSDD) | 2. | Summarize key data for new, intracrine-based therapy for dyspareunia |
3. | Discuss potential therapies in development for the treatment of dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) | 4. | Summarize key safety and efficacy information on traditional therapies for Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) |
1. | Discuss how the science of Intracrinology and DHEA relates to the physiologic, histologic and morphologic changes associated with menopause and treatment of dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM), and potentially Hypoactive Sexual Desire Disorder (HSDD) |
2. | Summarize key data for new, intracrine-based therapy for dyspareunia |
3. | Discuss potential therapies in development for the treatment of dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) |
4. | Summarize key safety and efficacy information on traditional therapies for Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) |
Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |